The GLAUrious consortium aims to complete the final steps in development of the EAGLE device, namely clinical validation of the prototype, commercial prototype production by cost optimization of components, dissemination to key opinion leaders and distributors, and refinement of the commercial strategy. Successful validation of EAGLE will result in its commercialization enabling, on one hand, substantial penetration by this innovative product of the ophthalmic market, and on the other hand boosting growth of the industrial consortium partners.